Phage therapy of E coli infections
AssigneePherecydes Pharma
InventorsFlavie Pouillot, Hélène Blois
Life of this patent
Estimating the term…
Abstract
The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
Claims14
A method of treating of an infection in a mammal in need thereof, comprising administering to the mammal infected with an Escherichia coli (E. coli) strain an antibacterial composition in an amount effective to treat said E. coli infection, wherein said composition comprises at least two distinct bacteriophages having lytic activity to said E. coli strain, said at least two distinct bacteriophages being selected from the bacteriophages having a genome comprising a nucleotide sequence selected from any one of SEQ ID NOs:
- 1 to 15 or a sequence having at least 99% identity thereto.
A method for improving the condition of a mammal by modifying the microbial flora, comprising administering to the mammal an effective amount of an antibacterial composition, wherein said composition comprises at least two distinct bacteriophages having lytic activity to an Escherichia coli (E. coli) strain, said at least two distinct bacteriophages being selected from the bacteriophages having a genome comprising a nucleotide sequence selected from any one of SEQ ID NOs:
- 1 to 15 or a sequence having at least 99% identity thereto and said microbial flora comprises said E. coli strain.
A method for decontaminating a material, comprising exposing the material to an amount of an antibacterial composition effective to decontaminate said material, wherein said composition comprises at least two distinct bacteriophages having lytic activity to an Escherichia coli (E. coli) strain, said at least two distinct bacteriophages being selected from the bacteriophages having a genome comprising a nucleotide sequence selected from any one of SEQ ID NOs:
- 1 to 15 or a sequence having at least 99% identity thereto.
An antibacterial composition comprising at least two distinct bacteriophages having lytic activity to an Escherichia coli (E. coli) strain and a pharmaceutically acceptable excipient or carrier, said at least two distinct bacteriophages being selected from the bacteriophages having a genome comprising a nucleotide sequence selected from any one of SEQ ID NOs:
- 1 to 15 or a sequence having at least 99% identity thereto and said pharmaceutically acceptable excipient or carrier comprising a preservative in an amount effective to preserve the activity of the bacteriophages.
Dependencies are inferred from the claim text.